STOCK TITAN

Iovance Biotherapeutics, Inc. - $IOVA STOCK NEWS

Welcome to our dedicated page for Iovance Biotherapeutics news (Ticker: $IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iovance Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iovance Biotherapeutics's position in the market.

Rhea-AI Summary
Iovance Biotherapeutics grants inducement stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA): FDA Priority Review of Biologics License Application (BLA) for lifileucel in advanced melanoma is on track for potential approval and launch in 2023. The company reported second quarter and first half 2023 financial results, including corporate updates. The TIL program for post-Anti-PD-1 non-small cell lung cancer is advancing into registrational development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics announced the oral and poster presentations of clinical and preclinical data for tumor infiltrating lymphocyte (TIL) therapies at the IASLC 2023 World Conference on Lung Cancer. The presentations will include data from the Phase 2 clinical trial of LN-145 in combination with pembrolizumab in anti-PD1-naïve advanced non-small cell lung cancer (NSCLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences clinical trial
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will report its second quarter 2023 financial results on August 8, 2023. The company focuses on developing polyclonal tumor infiltrating lymphocyte therapies for cancer patients. A conference call and live webcast will be held at 4:30 p.m. ET. Registration is required to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences earnings
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of the grant of inducement stock options to 8 new non-executive employees. The options cover an aggregate of 71,800 shares of Iovance's common stock and have an exercise price of $7.62. The options vest over a three-year period, with one-third of the shares vesting on the first anniversary of the employee's start date and the remaining shares vesting in eight quarterly installments over the next two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics has closed an underwritten public offering of 23 million shares of its common stock at a price of $7.50 per share, raising $172.5 million. The company plans to use the proceeds for various purposes, including preparing for the commercial launch of lifileucel and supporting ongoing clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the pricing of an underwritten public offering of its common stock at $7.50 per share, with expected gross proceeds of approximately $150 million. The company intends to use the proceeds for various purposes including the commercial launch of lifileucel and the expansion of TIL and immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics receives positive FDA feedback for IOV-LUN-202 trial design in post-anti-PD-1 NSCLC. Preliminary data shows a 26.1% objective response rate with a disease control rate of 82.6%. Enrollment of approximately 120 patients expected to be complete by H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
Iovance Biotherapeutics, Inc.

Nasdaq:IOVA

IOVA Rankings

IOVA Stock Data

2.28B
210.92M
0.56%
89.18%
16.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN CARLOS